WallStSmart

Lineage, Inc. Common Stock (LINE)vsRMR Group Inc (RMR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 2303% more annual revenue ($5.36B vs $223.02M). RMR leads profitability with a 8.9% profit margin vs -2.7%. RMR earns a higher WallStSmart Score of 62/100 (C+).

LINE

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 5.0Quality: 3.0
Piotroski: 2/9Altman Z: 0.67

RMR

Buy

62

out of 100

Grade: C+

Growth: 3.3Profit: 6.5Value: 7.7Quality: 5.5
Piotroski: 2/9Altman Z: 2.98

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

RMR4 strengths · Avg: 8.5/10
PEG RatioValuation
0.0910/10

Growing faster than its price suggests

P/E RatioValuation
17.1x8/10

Attractively priced relative to earnings

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

Areas to Watch

LINE4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.4%4/10

0.4% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
3.3%3/10

Operating margin of 3.3%

Debt/EquityHealth
1.013/10

Elevated debt levels

RMR3 concerns · Avg: 2.7/10
Market CapQuality
$336.82M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-26.6%2/10

Earnings declined 26.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bull Case : RMR

The strongest argument for RMR centers on PEG Ratio, P/E Ratio, Price/Book. PEG of 0.09 suggests the stock is reasonably priced for its growth.

Bear Case : LINE

The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.

Bear Case : RMR

The primary concerns for RMR are Market Cap, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

LINE profiles as a turnaround stock while RMR is a value play — different risk/reward profiles.

RMR carries more volatility with a beta of 1.07 — expect wider price swings.

RMR is growing revenue faster at 8.4% — sustainability is the question.

LINE generates stronger free cash flow (131M), providing more financial flexibility.

Bottom Line

RMR scores higher overall (62/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm dedicated to regenerative medicine, focusing on next-generation cell therapies targeting ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust strategic collaborations, Lineage is at the forefront of developing transformative treatment options that aim to improve patient outcomes significantly. The company's commitment to enhancing its diverse product pipeline and expediting clinical trials makes it an attractive investment opportunity for institutional investors seeking exposure in the rapidly evolving healthcare landscape.

Visit Website →

RMR Group Inc

REAL ESTATE · REAL ESTATE SERVICES · USA

The RMR Group Inc., through its subsidiary, The RMR Group LLC, provides business and property management services in the United States. The company is headquartered in Newton, Massachusetts.

Visit Website →

Want to dig deeper into these stocks?